M&A - Cencora, Inc.

Form Type: 8-K

Filing Date: 2025-03-10

Corporate Action: Acquisition

Type: Update

Accession Number: 000110465925021947

Filing Summary: Cencora, Inc.'s executives will present at the Leerink Partners Global Healthcare Conference on March 10, 2025, providing updates on performance expectations and business developments, including an update to its fiscal year 2025 financial guidance. The adjusted diluted earnings per share (EPS) for fiscal 2025 is now expected to range from $15.30 to $15.60, an increase from the prior range of $15.25 to $15.55, reflecting continued momentum in the second quarter for its core U.S. Healthcare Solutions segment. This update does not change expectations regarding the recent acquisition of Retina Consultants of America. The document also includes forward-looking statements and provides supplemental information on non-GAAP financial measures, emphasizing the relevance of adjusted diluted EPS, which excludes impacts from various financial adjustments. Cencora intends to continue providing updates about its performance and financial outlook through its investor relations website, although the company retains the right to discontinue webcasts at any time.

Document Link: View Document

Form Type: 8-K

Filing Date: 2025-01-02

Corporate Action: Acquisition

Type: New

Accession Number: 000110465925000366

Filing Summary: On January 2, 2025, Cencora, Inc. completed the acquisition of Retina Midco, Inc., also known as Retina Consultants of America (RCA), from Webster Equity Partners. This acquisition follows a definitive agreement disclosed in an earlier filing on November 8, 2024. Cencora now holds approximately 85% ownership in RCA, while certain physicians and management team members retain a minority equity interest. The total cash outlay at closing for this acquisition was $4.4 billion, subject to customary post-closing price adjustments. A news release announcing the acquisition was issued on the same day, January 2, 2025.

Document Link: View Document